Crispr gene-editing drugs show promise in preliminary study

Intellia Therapeutics Inc. reported encouraging early study results for its Crispr gene-editing treatments, the latest sign that the breakthrough technology could result in commercially available drugs in the coming years.

Intellia said Friday that one of the treatments, codenamed NTLA-2002, reduced the levels of a protein that causes periodic bouts of swelling in six patients with a rare genetic disease called hereditary angioedema, or HAE.